TY - JOUR
T1 - Expression of activin and inhibin subunits, receptors and binding proteins in human adrenocortical neoplasms
AU - Hofland, J.
AU - Timmerman, M. A.
AU - De Herder, W. W.
AU - Van Schaik, R. H.N.
AU - De Krijger, R. R.
AU - De Jong, F. H.
PY - 2006/12
Y1 - 2006/12
N2 - Objective: The growth and differentiation factors activin and inhibin can affect tumour formation and steroid production in the adrenal cortex. These factors bind to type I (Alk-4), type II (ActRIIA, ActRIIB) and type III (betaglycan) receptors or to the activin-binding protein follistatin. Expression of these activin-related mRNAs was measured in different types of adrenocortical tissues and tumours to study the relationship with tumorigenesis. Design: Quantitative expression of activin-related mRNAs was investigated in patient adrenocortical samples. Patients: Twenty-eight human adrenocortical samples from normal and hyperplastic adrenals and from adrenocortical adenomas and carcinomas were collected after surgery for study purposes. Measurements: Using quantitative reverse transcription polymerase chain reaction (RT-PCR), we investigated the expression of inhibin α-, βA- and βB-subunits, follistatin, betaglycan, ActRIIA, ActRIIB and Alk-4 in the adrenocortical tissues. The expression of cytochrome P450c17 (CYP17) mRNA was also measured to investigate its association with inhibin and activin subunit expression. Results: All genes studied were expressed in all tissues, with the exception of the inhibin α-subunit in one hyperplastic adrenal and three adrenocortical carcinomas. Expression of inhibin βA-subunit, follistatin, betaglycan, ActRIIA, ActRIIB and CYP17 differed between nontumorous adrenals and carcinomas. Conclusions: These differences, together with correlation analysis, indicate parallel regulation of the expression of CYP17, the inhibin α-subunit, ActRIIA, ActRIIB, betaglycan and follistatin. We conclude that the expression of activin and inhibin subunits, receptors and binding proteins is affected by tumour formation in the adrenal gland and may play a role in tumorigenesis.
AB - Objective: The growth and differentiation factors activin and inhibin can affect tumour formation and steroid production in the adrenal cortex. These factors bind to type I (Alk-4), type II (ActRIIA, ActRIIB) and type III (betaglycan) receptors or to the activin-binding protein follistatin. Expression of these activin-related mRNAs was measured in different types of adrenocortical tissues and tumours to study the relationship with tumorigenesis. Design: Quantitative expression of activin-related mRNAs was investigated in patient adrenocortical samples. Patients: Twenty-eight human adrenocortical samples from normal and hyperplastic adrenals and from adrenocortical adenomas and carcinomas were collected after surgery for study purposes. Measurements: Using quantitative reverse transcription polymerase chain reaction (RT-PCR), we investigated the expression of inhibin α-, βA- and βB-subunits, follistatin, betaglycan, ActRIIA, ActRIIB and Alk-4 in the adrenocortical tissues. The expression of cytochrome P450c17 (CYP17) mRNA was also measured to investigate its association with inhibin and activin subunit expression. Results: All genes studied were expressed in all tissues, with the exception of the inhibin α-subunit in one hyperplastic adrenal and three adrenocortical carcinomas. Expression of inhibin βA-subunit, follistatin, betaglycan, ActRIIA, ActRIIB and CYP17 differed between nontumorous adrenals and carcinomas. Conclusions: These differences, together with correlation analysis, indicate parallel regulation of the expression of CYP17, the inhibin α-subunit, ActRIIA, ActRIIB, betaglycan and follistatin. We conclude that the expression of activin and inhibin subunits, receptors and binding proteins is affected by tumour formation in the adrenal gland and may play a role in tumorigenesis.
UR - http://www.scopus.com/inward/record.url?scp=33751089563&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2265.2006.02668.x
DO - 10.1111/j.1365-2265.2006.02668.x
M3 - Article
C2 - 17121532
AN - SCOPUS:33751089563
SN - 0300-0664
VL - 65
SP - 792
EP - 799
JO - Clinical Endocrinology
JF - Clinical Endocrinology
IS - 6
ER -